Clinical Trial

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-11; most recent amendment 2026-05-25.
Status change: Not Yet Recruiting → Recruiting 2024-05-12
Trial Details
NCT Number NCT06361888
Lead Sponsor Hutchmed
Conditions Metastatic Pancreatic Cancer
Enrollment 502 participants
Start Date 2024-05-08
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-28